At the recent yearly meeting of the American Urological Association in Chicago, an updated "best practice statement" with regards to prostate cancer screening was published. These guidelines were somewhat of a surprise in light of recent controversial publications regarding the effect of prostate cancer screening.

First, the age for obtaining a baseline PSA has been lowered to 40 years.

Secondly, the current policy no longer recommends a single threshold value of PSA which should prompt prostate biopsy. Rather, the decision to proceed to prostate biopsy should be based primarily on PSA and DRE results, but should take into account multiple factors including free and total PSA, patient age, PSA velocity, PSA density, family history, ethnicity, prior biopsy history and comorbidities.

For the complete text of the "best practice statement", follow this link:
http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf